1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Oxidative	_	_	JJ	_	_	_	_	_
2	stress	_	_	NN	_	_	_	_	_
3	was	_	_	VBD	_	_	_	_	_
4	identified	_	_	VBN	_	_	_	_	_
5	as	_	_	IN	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	hallmark	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	almost	_	_	RB	_	_	_	_	_
10	all	_	_	DT	_	_	_	_	_
11	cardiovascular	_	_	JJ	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	neurodegenerative	_	_	JJ	_	_	_	_	_
14	diseases	_	_	NNS	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	term	_	_	NN	_	_	_	_	_
3	oxidative	_	_	JJ	_	_	_	_	_
4	stress	_	_	NN	_	_	_	_	_
5	describes	_	_	VBZ	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	condition	_	_	NN	_	_	_	_	_
8	that	_	_	WDT	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	either	_	_	CC	_	_	_	_	_
11	characterized	_	_	VBN	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	increased	_	_	VBN	_	_	_	_	_
14	generation	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	reactive	_	_	JJ	_	_	_	_	_
17	oxygen	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	nitrogen	_	_	NN	_	_	_	_	_
20	species	_	_	NNS	_	_	_	_	_
21	(	_	_	-LRB-	_	_	_	_	_
22	RONS	_	_	NNS	_	_	_	_	_
23	)	_	_	-RRB-	_	_	_	_	_
24	and/or	_	_	,	_	_	_	_	_
25	dysregulated	_	_	VBN	_	_	_	_	_
26	cellular	_	_	JJ	_	_	_	_	_
27	antioxidant	_	_	JJ	_	_	_	_	_
28	defense	_	_	NN	_	_	_	_	_
29	mechanisms	_	_	NNS	_	_	_	_	_
30	(	_	_	-LRB-	_	_	_	_	_
31	e.	_	_	FW	_	_	_	_	_
32	g.	_	_	FW	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	decreased	_	_	VBN	_	_	_	_	_
35	expression	_	_	NN	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	central	_	_	JJ	_	_	_	_	_
38	antioxidant	_	_	NN	_	_	_	_	_
39	enzymes	_	_	NNS	_	_	_	_	_
40	)	_	_	-RRB-	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	will	_	_	MD	_	_	_	_	_
3	ultimately	_	_	RB	_	_	_	_	_
4	cause	_	_	VB	_	_	_	_	_
5	that	_	_	DT	_	_	_	_	_
6	tissue	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	plasma	_	_	NN	_	_	_	_	_
9	or	_	_	CC	_	_	_	_	_
10	intercellular	_	_	JJ	_	_	_	_	_
11	fluid	_	_	NN	_	_	_	_	_
12	run	_	_	VBN	_	_	_	_	_
13	out	_	_	RP	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	low	_	_	JJ	_	_	_	_	_
16	molecular	_	_	JJ	_	_	_	_	_
17	weight	_	_	NN	_	_	_	_	_
18	antioxidant	_	_	JJ	_	_	_	_	_
19	compounds	_	_	NNS	_	_	_	_	_
20	leading	_	_	VBG	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	detrimental	_	_	JJ	_	_	_	_	_
23	alterations	_	_	NNS	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	cellular	_	_	JJ	_	_	_	_	_
26	redox	_	_	NN	_	_	_	_	_
27	state	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	most	_	_	RBS	_	_	_	_	_
3	abundant	_	_	JJ	_	_	_	_	_
4	biological	_	_	JJ	_	_	_	_	_
5	RONS	_	_	NNS	_	_	_	_	_
6	include	_	_	VBP	_	_	_	_	_
7	superoxide	_	_	NN	_	_	_	_	_
8	radical	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	hydrogen	_	_	NN	_	_	_	_	_
11	peroxide	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	hydroxyl	_	_	NN	_	_	_	_	_
14	radical	_	_	JJ	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	carbon-centered	_	_	JJ	_	_	_	_	_
17	peroxides	_	_	NNS	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	peroxyl	_	_	NN	_	_	_	_	_
20	radicals	_	_	NNS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	nitric	_	_	NN	_	_	_	_	_
23	oxide	_	_	NN	_	_	_	_	_
24	radical	_	_	JJ	_	_	_	_	_
25	(	_	_	-LRB-	_	_	_	_	_
26	NO∙	_	_	NN	_	_	_	_	_
27	)	_	_	-RRB-	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	nitrogen	_	_	NN	_	_	_	_	_
30	dioxide	_	_	NN	_	_	_	_	_
31	radial	_	_	NN	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	peroxynitrite	_	_	NN	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	and	_	_	CC	_	_	_	_	_
36	hypochlorite	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	Some	_	_	DT	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	these	_	_	DT	_	_	_	_	_
4	species	_	_	NNS	_	_	_	_	_
5	were	_	_	VBD	_	_	_	_	_
6	reported	_	_	VBN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	act	_	_	VB	_	_	_	_	_
9	as	_	_	IN	_	_	_	_	_
10	cellular	_	_	JJ	_	_	_	_	_
11	messengers	_	_	NNS	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	participate	_	_	VB	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	redox	_	_	NN	_	_	_	_	_
16	signaling	_	_	NN	_	_	_	_	_
17	mechanisms	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Nitric	_	_	NN	_	_	_	_	_
2	oxide	_	_	NN	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	NO∙	_	_	NNP	_	_	_	_	_
5	)	_	_	-RRB-	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	instance	_	_	NN	_	_	_	_	_
8	acts	_	_	VBZ	_	_	_	_	_
9	as	_	_	IN	_	_	_	_	_
10	an	_	_	DT	_	_	_	_	_
11	important	_	_	JJ	_	_	_	_	_
12	vasodilator	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	inhibitor	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	platelet	_	_	NN	_	_	_	_	_
17	activation	_	_	NN	_	_	_	_	_
18	via	_	_	IN	_	_	_	_	_
19	formation	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	nitrosyl-iron	_	_	NN	_	_	_	_	_
22	enzyme	_	_	NN	_	_	_	_	_
23	complexes	_	_	NNS	_	_	_	_	_
24	but	_	_	CC	_	_	_	_	_
25	also	_	_	RB	_	_	_	_	_
26	provides	_	_	VBZ	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	basis	_	_	NN	_	_	_	_	_
29	for	_	_	IN	_	_	_	_	_
30	wide-spread	_	_	JJ	_	_	_	_	_
31	signaling	_	_	NN	_	_	_	_	_
32	mechanisms	_	_	NNS	_	_	_	_	_
33	by	_	_	IN	_	_	_	_	_
34	S-nitros(yl)ation	_	_	NN	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	protein	_	_	NN	_	_	_	_	_
37	thiol	_	_	NN	_	_	_	_	_
38	groups	_	_	NNS	_	_	_	_	_
39	as	_	_	IN	_	_	_	_	_
40	exemplified	_	_	VBN	_	_	_	_	_
41	by	_	_	IN	_	_	_	_	_
42	suppression	_	_	NN	_	_	_	_	_
43	of	_	_	IN	_	_	_	_	_
44	apoptosis	_	_	NN	_	_	_	_	_
45	by	_	_	IN	_	_	_	_	_
46	S-nitros(yl)ation	_	_	NN	_	_	_	_	_
47	of	_	_	IN	_	_	_	_	_
48	caspases	_	_	NNS	_	_	_	_	_
49	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	superoxide	_	_	NN	_	_	_	_	_
3	radical	_	_	JJ	_	_	_	_	_
4	anion	_	_	NN	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	O2∙−	_	_	NNP	_	_	_	_	_
7	)	_	_	-RRB-	_	_	_	_	_
8	can	_	_	MD	_	_	_	_	_
9	be	_	_	VB	_	_	_	_	_
10	formed	_	_	VBN	_	_	_	_	_
11	from	_	_	IN	_	_	_	_	_
12	different	_	_	JJ	_	_	_	_	_
13	sources	_	_	NNS	_	_	_	_	_
14	such	_	_	JJ	_	_	_	_	_
15	as	_	_	IN	_	_	_	_	_
16	xanthine	_	_	NN	_	_	_	_	_
17	oxidase	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	NADPH	_	_	NN	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	nicotinamide	_	_	NN	_	_	_	_	_
22	adenine	_	_	NN	_	_	_	_	_
23	dinucleotide	_	_	NN	_	_	_	_	_
24	phosphate	_	_	NN	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	oxidases	_	_	NNS	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	uncoupled	_	_	VBN	_	_	_	_	_
29	NO	_	_	DT	_	_	_	_	_
30	synthases	_	_	NNS	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	the	_	_	DT	_	_	_	_	_
33	mitochondrial	_	_	JJ	_	_	_	_	_
34	respiratory	_	_	JJ	_	_	_	_	_
35	chain	_	_	NN	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	represent	_	_	VBP	_	_	_	_	_
39	in	_	_	IN	_	_	_	_	_
40	many	_	_	JJ	_	_	_	_	_
41	ways	_	_	NNS	_	_	_	_	_
42	a	_	_	DT	_	_	_	_	_
43	direct	_	_	JJ	_	_	_	_	_
44	antagonist	_	_	NN	_	_	_	_	_
45	of	_	_	IN	_	_	_	_	_
46	nitric	_	_	NN	_	_	_	_	_
47	oxide	_	_	NN	_	_	_	_	_
48	as	_	_	IN	_	_	_	_	_
49	shown	_	_	VBN	_	_	_	_	_
50	by	_	_	IN	_	_	_	_	_
51	the	_	_	DT	_	_	_	_	_
52	famous	_	_	JJ	_	_	_	_	_
53	experiment	_	_	NN	_	_	_	_	_
54	by	_	_	IN	_	_	_	_	_
55	Gryglewski	_	_	NNP	_	_	_	_	_
56	et	_	_	FW	_	_	_	_	_
57	al.	_	_	FW	_	_	_	_	_
58	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	existence	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	superoxide	_	_	NN	_	_	_	_	_
5	dismutases	_	_	NNS	_	_	_	_	_
6	(	_	_	-LRB-	_	_	_	_	_
7	mitochondrial	_	_	JJ	_	_	_	_	_
8	MnSOD	_	_	NNP	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	cytosolic/extracellular	_	_	JJ	_	_	_	_	_
11	Cu	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	Zn-SOD	_	_	NNP	_	_	_	_	_
14	)	_	_	-RRB-	_	_	_	_	_
15	implies	_	_	VBZ	_	_	_	_	_
16	that	_	_	IN	_	_	_	_	_
17	superoxide	_	_	NN	_	_	_	_	_
18	may	_	_	MD	_	_	_	_	_
19	be	_	_	VB	_	_	_	_	_
20	harmful	_	_	JJ	_	_	_	_	_
21	for	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	cell	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	which	_	_	WDT	_	_	_	_	_
26	is	_	_	VBZ	_	_	_	_	_
27	supported	_	_	VBN	_	_	_	_	_
28	by	_	_	IN	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	fact	_	_	NN	_	_	_	_	_
31	that	_	_	IN	_	_	_	_	_
32	deficiency	_	_	NN	_	_	_	_	_
33	in	_	_	IN	_	_	_	_	_
34	MnSOD	_	_	NNP	_	_	_	_	_
35	is	_	_	VBZ	_	_	_	_	_
36	lethal	_	_	JJ	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	deficiency	_	_	NN	_	_	_	_	_
39	in	_	_	IN	_	_	_	_	_
40	Cu	_	_	NNP	_	_	_	_	_
41	,	_	_	,	_	_	_	_	_
42	Zn-SOD	_	_	NNP	_	_	_	_	_
43	renders	_	_	VBZ	_	_	_	_	_
44	mice	_	_	NNS	_	_	_	_	_
45	susceptible	_	_	JJ	_	_	_	_	_
46	to	_	_	TO	_	_	_	_	_
47	cardiovascular	_	_	JJ	_	_	_	_	_
48	and	_	_	CC	_	_	_	_	_
49	neuronal	_	_	JJ	_	_	_	_	_
50	complications	_	_	NNS	_	_	_	_	_
51	.	_	_	.	_	_	_	_	_


1	Since	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	transition	_	_	NN	_	_	_	_	_
4	between	_	_	IN	_	_	_	_	_
5	oxidative	_	_	JJ	_	_	_	_	_
6	stress	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	redox	_	_	NN	_	_	_	_	_
9	signaling	_	_	NN	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	thin	_	_	JJ	_	_	_	_	_
13	line	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	exact	_	_	JJ	_	_	_	_	_
17	knowledge	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	identity	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	formed	_	_	VBN	_	_	_	_	_
23	species	_	_	NNS	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	cellular	_	_	JJ	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	subcellular	_	_	JJ	_	_	_	_	_
29	localization	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	their	_	_	PRP$	_	_	_	_	_
32	formation	_	_	NN	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	as	_	_	RB	_	_	_	_	_
35	well	_	_	RB	_	_	_	_	_
36	as	_	_	IN	_	_	_	_	_
37	their	_	_	PRP$	_	_	_	_	_
38	time	_	_	NN	_	_	_	_	_
39	duration	_	_	NN	_	_	_	_	_
40	and	_	_	CC	_	_	_	_	_
41	concentration	_	_	NN	_	_	_	_	_
42	,	_	_	,	_	_	_	_	_
43	are	_	_	VBP	_	_	_	_	_
44	of	_	_	IN	_	_	_	_	_
45	high	_	_	JJ	_	_	_	_	_
46	clinical	_	_	JJ	_	_	_	_	_
47	and	_	_	CC	_	_	_	_	_
48	pharmacological	_	_	JJ	_	_	_	_	_
49	importance	_	_	NN	_	_	_	_	_
50	.	_	_	.	_	_	_	_	_


1	With	_	_	IN	_	_	_	_	_
2	our	_	_	PRP$	_	_	_	_	_
3	previous	_	_	JJ	_	_	_	_	_
4	work	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	we	_	_	PRP	_	_	_	_	_
7	have	_	_	VBP	_	_	_	_	_
8	stressed	_	_	VBN	_	_	_	_	_
9	that	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	traditional	_	_	JJ	_	_	_	_	_
12	or	_	_	CC	_	_	_	_	_
13	old	_	_	JJ	_	_	_	_	_
14	RONS	_	_	NNP	_	_	_	_	_
15	assays	_	_	NNS	_	_	_	_	_
16	are	_	_	VBP	_	_	_	_	_
17	not	_	_	RB	_	_	_	_	_
18	necessarily	_	_	RB	_	_	_	_	_
19	inferior	_	_	JJ	_	_	_	_	_
20	as	_	_	IN	_	_	_	_	_
21	compared	_	_	VBN	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	up-to-date	_	_	JJ	_	_	_	_	_
24	or	_	_	CC	_	_	_	_	_
25	even	_	_	RB	_	_	_	_	_
26	cutting-edge	_	_	JJ	_	_	_	_	_
27	assays	_	_	NNS	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	at	_	_	IN	_	_	_	_	_
30	least	_	_	JJS	_	_	_	_	_
31	have	_	_	VBP	_	_	_	_	_
32	their	_	_	PRP$	_	_	_	_	_
33	specific	_	_	JJ	_	_	_	_	_
34	features	_	_	NNS	_	_	_	_	_
35	and	_	_	CC	_	_	_	_	_
36	application	_	_	NN	_	_	_	_	_
37	spectra	_	_	NNS	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	With	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	present	_	_	JJ	_	_	_	_	_
4	studies	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	we	_	_	PRP	_	_	_	_	_
7	evaluated	_	_	VBD	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	specific	_	_	JJ	_	_	_	_	_
10	probe	_	_	NN	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	mitochondrial	_	_	JJ	_	_	_	_	_
13	superoxide	_	_	NN	_	_	_	_	_
14	formation	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	mitochondria-targeted	_	_	JJ	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	triphenylphosphonium-linked	_	_	JJ	_	_	_	_	_
19	hydroethidium	_	_	NN	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	mitoSOX	_	_	NN	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	for	_	_	IN	_	_	_	_	_
25	its	_	_	PRP$	_	_	_	_	_
26	usefulness	_	_	NN	_	_	_	_	_
27	in	_	_	IN	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	detection	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	mitochondrial	_	_	JJ	_	_	_	_	_
32	superoxide	_	_	NN	_	_	_	_	_
33	formation	_	_	NN	_	_	_	_	_
34	ex	_	_	NN	_	_	_	_	_
35	vivo/in	_	_	NN	_	_	_	_	_
36	vivo	_	_	NN	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	compared	_	_	VBN	_	_	_	_	_
39	this	_	_	DT	_	_	_	_	_
40	high-performance/pressure	_	_	JJ	_	_	_	_	_
41	liquid	_	_	NN	_	_	_	_	_
42	chromatography	_	_	NN	_	_	_	_	_
43	(	_	_	-LRB-	_	_	_	_	_
44	HPLC)-based	_	_	JJ	_	_	_	_	_
45	assay	_	_	NN	_	_	_	_	_
46	with	_	_	IN	_	_	_	_	_
47	two	_	_	CD	_	_	_	_	_
48	alternative/traditional	_	_	JJ	_	_	_	_	_
49	methods	_	_	NNS	_	_	_	_	_
50	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	purpose	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	used	_	_	VBD	_	_	_	_	_
7	three	_	_	CD	_	_	_	_	_
8	different	_	_	JJ	_	_	_	_	_
9	animal	_	_	NN	_	_	_	_	_
10	models	_	_	NNS	_	_	_	_	_
11	with	_	_	IN	_	_	_	_	_
12	well	_	_	RB	_	_	_	_	_
13	established	_	_	VBN	_	_	_	_	_
14	oxidative	_	_	JJ	_	_	_	_	_
15	stress	_	_	NN	_	_	_	_	_
16	burden	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	namely	_	_	RB	_	_	_	_	_
19	diabetic	_	_	JJ	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	hypertensive	_	_	JJ	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	nitrate	_	_	NN	_	_	_	_	_
24	tolerant	_	_	JJ	_	_	_	_	_
25	rats	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Given	_	_	VBN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	recent	_	_	JJ	_	_	_	_	_
4	report	_	_	NN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	Xiao	_	_	NNP	_	_	_	_	_
7	&	_	_	CC	_	_	_	_	_
8	Meierhofer	_	_	NNP	_	_	_	_	_
9	raising	_	_	VBG	_	_	_	_	_
10	doubts	_	_	NNS	_	_	_	_	_
11	about	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	reliable	_	_	JJ	_	_	_	_	_
14	use	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	hydroethidium-based	_	_	JJ	_	_	_	_	_
17	probes	_	_	NNS	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	superoxide	_	_	NN	_	_	_	_	_
20	detection	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	cell	_	_	NN	_	_	_	_	_
23	culture	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	we	_	_	PRP	_	_	_	_	_
26	think	_	_	VBP	_	_	_	_	_
27	that	_	_	IN	_	_	_	_	_
28	our	_	_	PRP$	_	_	_	_	_
29	present	_	_	JJ	_	_	_	_	_
30	data	_	_	NNS	_	_	_	_	_
31	are	_	_	VBP	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	interest	_	_	NN	_	_	_	_	_
34	for	_	_	IN	_	_	_	_	_
35	all	_	_	DT	_	_	_	_	_
36	researchers	_	_	NNS	_	_	_	_	_
37	using	_	_	VBG	_	_	_	_	_
38	hydroethidium-based	_	_	JJ	_	_	_	_	_
39	probes	_	_	NNS	_	_	_	_	_
40	,	_	_	,	_	_	_	_	_
41	but	_	_	CC	_	_	_	_	_
42	especially	_	_	RB	_	_	_	_	_
43	mitoSOX	_	_	NNP	_	_	_	_	_
44	,	_	_	,	_	_	_	_	_
45	in	_	_	IN	_	_	_	_	_
46	cell	_	_	NN	_	_	_	_	_
47	culture	_	_	NN	_	_	_	_	_
48	,	_	_	,	_	_	_	_	_
49	isolated	_	_	VBN	_	_	_	_	_
50	mitochondria	_	_	NN	_	_	_	_	_
51	and	_	_	CC	_	_	_	_	_
52	tissue	_	_	NN	_	_	_	_	_
53	samples	_	_	NNS	_	_	_	_	_
54	.	_	_	.	_	_	_	_	_

